New Possibilities In Low-voltage Analog Circuit Design Using Dtmos Transistors

(Doktora) -- İstanbul Teknik Üniversitesi, Fen Bilimleri Enstitüsü, 2013(PhD) -- İstanbul Technical University, Institute of Science and Technology, 2013Bu çalışmada DTMOS yaklaşımı çok düşük besleme gerilimlerinde çalışan çok düşük güç tüketimli devrelere başarıyla uygulanmıştır. Tasarlanan devreler arasında OTA, OP-AMP, CCII gibi analog aktif yapı blokları, çarpma devresi, sadece-MOS yapılar gibi devreler bulunmaktadır. Tasarlanan devreler SPICE benzetimleri ile doğrulanmıştır. İleri yönde gövde kutuplamaya bağlı olarak DTMOS transistorun yapısından kaynaklanan, efektif olarak düşük eşik gerilimli çalışma özelliği nedeniyle, çok düşük güç tüketimli ve çok düşük gerilimli devrelerde DTMOS yaklaşımının geçerli bir alternatif olduğu bu çalışmayla gösterilmiştir. DTMOS yaklaşımının geniş bir alanda çeşitlilik gösteren analog devre yapılarında çok düşük besleme gerilimlerinde bile kabul edilebilir bir performansla kullanılabileceği bulunmuştur.In this study, DTMOS approach to the design of ultra low-voltage and ultra low-power analog circuits, has been successfully applied to the circuits ranging from EEG filtering circuits, speech processing filters in hearing aids, multipliers, analog active building blocks: OTA, OP-AMP, CCII to MOS-only circuits. The proposed circuits are verified with SPICE simulations. It is found that in designing ultra low-voltage, ultra low-power analog circuits, DTMOS approach is a viable alternative due to its inherent characteristic of effective low threshold voltage behaviour under forward body bias. This approach can be applied to several analog application subjects with acceptable performance under even ultra low supply voltages.DoktoraPh

An Ultra Low-Voltage Ultra Low-Power Memristor

Memristor can provide new approaches especially in nonlinear & chaotic circuit design. Since no commercially available memristor exist until yet, obtaining of a practical implementation which behaves as a memristor, is very important from the point of view real-world circuit design. In this work, an ultra low-voltage ultra low-power DTMOS-based design of memristor is presented. A new ultra low-voltage, ultra low-power operational amplifier and a new ultra low-voltage, ultra low-power multiplier are also proposed to use in the realization. Our design is composed of these two type active blocks using CMOS 0.18 mu m process technology with symmetric +/- 0.25V supply voltages. Characteristics and performance of our design is verified by PSPICE simulations. Total power consumption of the proposed memristor is found as just 4.3 mu W which is suitable for ultra low-power consumption. The simulation results show that our design provides the characteristics of memristor accurately and it could be a viable and convenient option especially in low-voltage low-power memristor based chaotic applications

Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects

Meloxicam (CAS 71125-38-7), a non-steroidal anti-inflammatory drug (NSAID), is used for the treatment of osteoarthritis and rheumatic arthritis. In the present study, two different oral meloxicam formulations (Melcam (R) 15 mg tablets as test preparation and tablets of a reference preparation) were investigated in 24 healthy male subjects in order to prove bioequivalence between both preparations. A single 15 mg oral dose was administered according to an open, randomised, two-period cross-over design in the fasted state. Blood samples for the determination of meloxicam plasma concentrations were collected at pre-defined time points up to 96 h following drug administration. A wash-out period of 7-8 days separated both treatment periods. Meloxicam plasma concentrations were determined by means of a validated HPLC method with UV-detection. Maximum plasma concentrations (C-max) of 1,146.9 ng/ml (test) and 1,064.8 ng/nil (reference) were achieved. Areas under the plasma concentration-time curve (AUC(0-infinity)) of 34,499.0 ng - h/nd (test) and 33,784.3 ng . h/ml (reference) were determined. The results showed nearly identical rate and extent of drug absorption. Also further pharmacokinetic parameters were well comparable. Thus, t(max) showed values of 5.00 h for both test and reference. The plasma elimination half-life t(1/2)) was 18.29 h (test) und 18.94 h (reference). Both primary target parameters C-max and AUC(0-infinity) were tested parametrically by analysis of variance (ANOVA) and the 90% confidence intervals were between 99.46%-105.24% (AUC(0-infinity)) and 103.37%-112.46% (C-max). Bioequivalence between test and reference preparation was demonstrated since for both parameters AUC and C-max the 90% confidence intervals of the T/R ratios of logarithmically transformed data were in the generally accepted range of 80%-125 %

Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects

The aim of the present study was to compare the bioavailability of doxycycline (CAS 564-25-0) from two different doxycycline hyclate (CAS 24390-14-5) capsules (Monodoks((R)) 100 mg capsule as test preparation and 100 mg capsule of the originator product as reference preparation) in 24 healthy male subjects. The study was conducted according to an open-label, randomised two-period cross-over design with a wash-out phase of 16 days. Blood samples for pharmacokinetic profiling were taken up to 72 h post-dose, and doxycycline plasma concentrations were determined with a validated HPLC method with UV-detection